RE
REDOXIS AB
Grant-FundedCORDISDevelopment of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.
Biotech
REDOXIS AB is a private SME recorded in CORDIS in Sweden, with participation in 6 EU research and innovation projects. Its recorded projects include “Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.”. CORDIS records describe funded project participation; they do not confirm current fundraising or consortium availability.
EU Grants€1,598,994
All-time revenue—
MRRPrivate••••••
Founder—
Founded—
🇸🇪Sweden
RevenuePrivate
Revenue data is privateThis company has chosen not to share revenue metrics
Startup insights
Value proposition
REDOXIS AB is a private SME recorded in CORDIS in Sweden, with participation in 6 EU research and innovation projects. Its recorded projects include “Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation.”. CORDIS records describe funded project participation; they do not confirm current fundraising or consortium availability.
Biotech
Tags:Biotech
Company Info
REDOXIS AB Info
Funding
EU Grants€1,598,994